Specialising in engineering consultancy and establishing rebuilding and optimising pharmaceutical production facilities, the company has a new Swedish subsidiary located in Huddinge south of Stockholm.

Specialising in engineering consultancy and establishing, rebuilding and optimising pharmaceutical production facilities, the company has set up a Swedish subsidiary located in Huddinge south of Stockholm. The decision to establish NNE Sweden AB was triggered by the increase in turnover in Sweden, where NNE has recorded sales running into double-digit millions (DDK). 'The new offices in Huddinge gives us an even better platform for serving existing and potential customers in Sweden,' said Kay Stendevad, managing director of NNE Sweden.

'We are both local and international players.

We aim to build an independent Swedish organisation focusing on local customers.

Coupled with our international experiences, our extensive network means we can meet all our clients' needs for consulting and engineering services.

Our skills cover a breadth and depth of disciplines'.

The NNE Swedish client base includes AstraZeneca, Pfizer/Pharmacia, Ferring, Novozymes Biopharma and Polypeptide.

The services most in demand are in the fields of automation, GMP and validation, process operations and clean room technology.

NNE Sweden AB has hired five engineers to date, all with experience from the pharmaceutical and biotech industries.

Further recruitment is underway.

The Huddinge premises will be officially inaugurated at a reception on 9 October 2003.

NNE has more than 80 years' experience as a supplier of consultancy and engineering services and process plants for the international pharmaceutical and biotechnological industries.

With a staff of more than 1,000, NNE is the largest Nordic consultancy in this segment.

NNE A/S is a wholly-owned subsidiary of the Danish pharmaceutical company Novo Nordisk A/S.